1. Home
  2. ILMN vs PUK Comparison

ILMN vs PUK Comparison

Compare ILMN & PUK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ILMN
  • PUK
  • Stock Information
  • Founded
  • ILMN 1998
  • PUK 1848
  • Country
  • ILMN United States
  • PUK Hong Kong
  • Employees
  • ILMN N/A
  • PUK N/A
  • Industry
  • ILMN Medical Specialities
  • PUK Life Insurance
  • Sector
  • ILMN Health Care
  • PUK Finance
  • Exchange
  • ILMN Nasdaq
  • PUK Nasdaq
  • Market Cap
  • ILMN 22.9B
  • PUK N/A
  • IPO Year
  • ILMN 2000
  • PUK 1990
  • Fundamental
  • Price
  • ILMN $142.50
  • PUK $16.41
  • Analyst Decision
  • ILMN Buy
  • PUK
  • Analyst Count
  • ILMN 20
  • PUK 0
  • Target Price
  • ILMN $160.68
  • PUK N/A
  • AVG Volume (30 Days)
  • ILMN 2.2M
  • PUK 1.1M
  • Earning Date
  • ILMN 11-04-2024
  • PUK 08-28-2024
  • Dividend Yield
  • ILMN N/A
  • PUK 2.56%
  • EPS Growth
  • ILMN N/A
  • PUK N/A
  • EPS
  • ILMN N/A
  • PUK 0.32
  • Revenue
  • ILMN $4,390,000,000.00
  • PUK $10,944,000,000.00
  • Revenue This Year
  • ILMN N/A
  • PUK N/A
  • Revenue Next Year
  • ILMN $4.28
  • PUK $11.71
  • P/E Ratio
  • ILMN N/A
  • PUK $24.65
  • Revenue Growth
  • ILMN N/A
  • PUK N/A
  • 52 Week Low
  • ILMN $97.36
  • PUK $15.11
  • 52 Week High
  • ILMN $156.66
  • PUK $22.93
  • Technical
  • Relative Strength Index (RSI)
  • ILMN 50.11
  • PUK 49.40
  • Support Level
  • ILMN $140.56
  • PUK $16.03
  • Resistance Level
  • ILMN $145.37
  • PUK $16.64
  • Average True Range (ATR)
  • ILMN 4.83
  • PUK 0.23
  • MACD
  • ILMN 0.13
  • PUK 0.08
  • Stochastic Oscillator
  • ILMN 77.84
  • PUK 75.53

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: